Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A compound of the formula:

$$\begin{array}{cccc}
& E \\
R^1-A-N & X-Y-Q-R^2 & & (I) \\
& & & & \\
R^3 & & R^4
\end{array}$$

wherein R1 is acyl;

R² is lower alkyl, lower alkoxy, lower alkylamino, lower alkenyl, lower alkynyloxy, lower alkynylamino, cyclo alkenyloxy, lower alkynyloxy, lower alkynylamino, cyclo (lower)alkyl, cyclo(lower)alkyloxy, cyclo(lower)alkylamino, aryl, aryloxy, arylamino, a heterocyclic group or amino substituted with a heterocyclic group, each of which may be substituted with a substituents(s); or acyl;

A is a single bond, -CO- or -SO₂-,

E is lower alkylene optionally substituted with substituent(s),

X is CH or N,

Y is a single bond, lower alkylene or -NR⁵-, [[(]]wherein R⁵ is hydrogen, lower alkyl, substituted-lower alkyl, an N-protective group, aryl, acyl or a heterocyclic group[[)]],

R³ and R⁴ are each hydrogen or lower alkyl, or taken together are lower_alkylene thereby forming a ring optionally condensed with a cyclic hydrocarbon or a heterocyclic ring, provided that when X is N, then 1) Y is a single bond, and Q is -CH₂-, -CO- or -SO₂-, or (2) Y is lower alkylene, and a pharmaceutically acceptable salt thereof; with the proviso that simultaneously A is not a single bond, E is not ethylene, X is not -CH-, Y is not -NH-, Q is not -CO- or SO₂- and R³ and R⁴ together are not ethylene.

Claim 2. (Currently Amended) The compound according to Claim 1, wherein R^2 is aryl, aryloxy or arylamino, each aryl of which may be substituted with haolgen; pyridyl; or pyridylamino;

A is a single bond,

E is ethylene,

X is N,

Y is a single bond, lower alkylene or -NR⁵- [[(]]wherein R⁵ is hydrogen, lower alkyl or an N-protective group[[)]],

Q is -CH₂-, -CO-, or -SO₂-, and

R³ and R⁴ taken together form ethylene.

Claim 3. (Previously Presented) The compound according to Claim 2, wherein

R¹ is lower alkanoyl, esterified carboxy, substituted or unsubstituted aroyl, lower alkylsulfonyl, substituted or unsubstituted arylsulfonyl, or cyclo(lower)alkylcarbonyl, and

R² is aryl or arylamino, each aryl of which may be substituted with halogen.

Claim 4. (Previously Presented) The compound according to Claim 3, wherein R¹ is lower alkanoyl, lower alkoxycarbonyl, aroyl, aroyl substituted with halo(lower)alkoxy, lower alkylsulfonyl, arylsulfonyl substituted with halogen, or cyclo(lower)alkylcarbonyl,

X is -CH-,

Y is a single bond, and

Q is -CO- or -SO₂-.

Claim 5. (Previously Presented) The compound according to Claim 3, wherein R¹ is lower alkanoyl, lower alkoxycarbonyl, aroyl, aroyl substituted with halo(lower)alkoxy, lower alkylsulfonyl, arylsulfonyl substituted with halogen, or cyclo(lower)alkylcarbonyl,

X is -N-,

Y is a single bond or lower alkylene, and

Q is -CO- or -SO₂-.

Claim 6. (Canceled)

Claim 7. (Previously Presented) The compound according to Claim 5, wherein Y is a single bond, and Q is -CO-.

Claim 8. (Currently Amended) A process for preparing a compound of the formula:

$$\begin{array}{c|cccc}
E & & & & & & & & & \\
R^1-A-N & & X-Y-Q-R^2 & & & & & & \\
& & & & & & & & \\
R^3 & & R^4 & & & & & & \\
\end{array}$$
(D)

wherein R¹ is acyl,

R² is lower alkyl, lower alkoxy, lower alkylamino, lower alkenyl, lower alkenyloxy, lower alkenylamino, lower alkynyl, lower alkynyloxy, lower alkynylamino, cyclo (lower)alkyl, cyclo(lower)alkyloxy, cyclo(lower)alkylamino, aryl, aryloxy, arylamino, a heterocyclic group or amino substituted with a heterocyclic group, each of which may be substituted with a substituents(s); or acyl;

A is a single bond, -CO- or -SO₂-,

E is lower alkylene optionally substituted with substituent(s),

X is CH or N,

Y is a single bond, lower alkylene or -NR⁵- [[(]]wherein R⁵ is hydrogen, lower alkyl, substituted-lower alkyl, an N-protective group, aryl, acyl or a heterocyclic group[[)]],

R³ and R⁴ are each hydrogen or lower alkyl, or taken together are lower alkylene thereby forming a ring optionally condensed with a cyclic hydrocarbon or a heterocyclic ring, provided that when X is N, then 1) Y is a single bond, and Q is -CH₂-, -CO-or -SO₂-, or (2) Y is lower alkylene, or <u>a</u> pharmaceutically acceptable salt thereof; with the proviso that simultaneously A is not a single bond, E is not ethylene, X is not -CH-, Y is not -NH-, Q is not -CO- or SO₂- and R³ and R⁴ together are not ethylene, which comprises:

1) reacting a compound of the formula:

$$R^{1}$$
-A-N NH (II)

or its salt with a compound of the formula:

$$HO-Q_a-R^2$$
 (III)

or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a compound of the formula:

$$R^{1}$$
-A-N N -Q_a-R² (Ia)

or its salt, in the above formulas, R^1 , R^2 , R^3 , R^4 , A and E are each as defined above, and Q_a is -CO- or -SO₂-.

(2) reacting a compound of the formula:

$$R^{1}$$
-A-N NH (II)

or its salt with a compound of the formula:

$$R^6$$
-NCO (IV)

to provide a compound of the formula:

$$\begin{array}{c|cccc}
E & O \\
II \\
R^1-A-N & N-CNH-R^6 \\
& & & \\
R^3 & R^4
\end{array} (Ib)$$

or its salt, wherein, in the above formulas, R^1 , R^3 , R^4 , A and E are each as defined above, and R^6 is aryl which may be substituted with substituent(s); or pyridyl, or

(3) reacting a compound of the formula:

$$R^{1}$$
-A-N CH -NH₂ (V)

or its salt with a compound of the formula:

$$HO-Q_a-R^2$$
 (III)

or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a compound of the formula:

$$R^{1}$$
-A-N CH-NHCONH-R⁶ (Id)

or its salt, wherein, in the above formulas, R¹, R², R³, R⁴, A, E and Q_a are each as defined above, or

4) reacting a compound of the formula:

$$R^{1}$$
-A-N CH -NH₂ (V)

or its salt with a compound of the formula:

$$R^6$$
 NCO (IV)

to provide a compound of the formula:

$$R^{1}$$
-A-N CH -NHCNH-R⁶ (Id)

or its salt, in the above formulas, R¹, R³, R⁴, R⁶, A and E are each as defined above, or 5) reacting a compound of the formula:

$$\begin{array}{ccc}
E \\
HN & X-Y-Q-R^2 \\
R^3 & R^4
\end{array} (VI)$$

or its salt with a compound of the formula:

$$R^1$$
-A-OH (VII)

or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a

compound of the formula:

$$\begin{array}{ccc}
E \\
R^{1}-A-N & X-Y-Q-R^{2} \\
\downarrow & \downarrow \\
R^{3} & R^{4}
\end{array} \tag{I}$$

or its salt, in the above formulas, R¹, R², R³, R⁴, A, E, X, Y and Q are each as defined above, or

6) reacting a compound of the formula:

$$R^{1}$$
-A-N X-Q_a-OH (VI)
 R^{3} R^{4}

or its reactive derivatives at the carboxy or sulfo group, or a salt thereof with a compound of the formula:

$$H_2N-R^7$$
 (IX)

or its salt to provide a compound of the formula:

$$R^{1}$$
-A-N X-Q_a-NH-R⁷ (Ie)

or its salt, in the above formulas, R¹, R³, R⁴, A, E, X and Q_a are each as defined above, and R⁷ is lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, aryl, or a heterocyclic group, each of which may be substituted with a substituents(s), or

7) reacting a compound of the formula:

$$R^{1}$$
-A-N CH -NH- R_a^{5} (X)

or its salt with a compound of the formula:

$$R_a^2 - Q_b - Z_a$$
 (XI)

to provide a compound of the formula:

$$R^{1}$$
-A-N CH -N R_{a}^{5} -Q_b- R_{a}^{2} (If)

or its salt, in the above formulas, R¹, R³, R⁴, A and E are each as defined above,

R_a⁵ is an N-protective group,

R_a² is lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, aryl, or a heterocyclic group, each of which may be substituted with a substituents(s),

Z_a is an acid residue, or

8) subjecting a compound of the formula:

$$R^{1}-A-N$$
 $CH-NR_{a}^{5}-Q_{b}-R_{a}^{2}$
(If)

or its salt to elimination of the N-protective group to provide a compound of

the formula:

$$R^{1}$$
-A-N CH-NH- Q_{b} - R_{a}^{2} (Ig)

or its salt, in the above formulas, R¹, R_a², R³, R⁴, A, E and Q_b, are each as defined above, or 9) reacting a compound of the formula:

$$R^{1}$$
-A-N CH-NH- Q_{c} - R_{a}^{5} (Ih)

or its salt with a compound of the formula:

$$R_b^5 - Z_b$$
 (XII)

to provide a compound of the formula:

$$R^{1}$$
-A-N CH -N R_{b}^{5} -Q_c- R_{a}^{2} (Ii)

or its salt, in the above formulas, R^1 , R_a^2 , R^3 , R^4 , A and E are each as defined above, Z_b is an acid residue,

Q_c is -CO-, and

R_b⁵ is lower alkyl, or

10) reacting a compound of the formula:

$$R^{1}$$
-A-N NH (II)

or its salt with a compound of the formula:

$$Z_c-Y_a-Q_a-R^2$$
 (XIII)

to provide a compound of the formula:

$$R^{1}-A-N$$
 $N-Y_{a}-Q_{a}-R^{2}$ (Ij)

or its salt, in the above formulas, R^1 , R^2 , R^3 , R^4 , A, E and Q_a are each as defined above, Z_c is an acid residue, and R_b^5 is lower alkylene.

Claim 9. (Previously Presented) A pharmaceutical composition, comprising:

a compound of Claim 1, as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claims 10-12. (Canceled)

Claim 13. (New) A compound of the formula:

$$R^1-N$$
 $N-Y-Q-R^2$

wherein R¹ is lower alkanoyl, aroyl, aroyl substituted by halo(lower)alkoxy, arylsulfonyl, arylsulfonyl substituted by halogen, lower alkylsulfonyl or cyclo(lower)alkylcarbonyl;

R² is lower alkylamino, lower alkenylamino, lower alkynylamino, cyclo(lower)alkylamino, arylamino or an amino group substituted with a heterocyclic group which is optionally substituted with halogen;

Y is a single bond or lower alkylene; and

Q is -CO- or -SO₂-, and a pharmaceutically acceptable salt thereof.

Claim 14. (New) The compound according to Claim 13, wherein

R² is arylamino which optionally is substituted by halogen, pyridyl, or pyridylamino.

Claim 15. (New) The compound according to Claim 13, which is 1-acetyl-4-(4-fluorophenylcarbamoyl)piperazine.

Claim 16. (New) A process for preparing a compound of the formula:

$$R^1-N$$
 $N-Y-Q-R^2$

wherein R¹ is lower alkanoyl, aroyl, aroyl substituted by halo(lower)alkoxy, arylsulfonyl, arylsulfonyl substituted by halogen, lower alkylsulfonyl or cyclo(lower)alkylcarbonyl;

R² is lower alkylamino, lower alkenylamino, lower alkynylamino, cyclo(lower)alkylamino, arylamino, an amino group that is substituted by a heterocyclic group, optionally substituted by a substituents(s);

Y is a single bond or lower alkylene; and

Q is -CO- or $-SO_2$ -, or a pharmaceutically acceptable salt thereof, which comprises:

1) reacting a compound of the formula:

$$R^1-N$$
 $N-H$
 (II)

or its salt with a compound of the formula:

$$HO-Q-R^2$$
 (III)

or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a compound of the formula:

$$R^1-N$$
 $N-Q-R^2$ (Ia)

or its salt, in the above formulas, R1, R2 and Q are each as defined above;

(2) reacting a compound of the formula:

$$R^1-N$$
 $N-H$ (II)

or its salt with a compound of the formula:

$$R^6$$
-NCO (IV)

to provide a compound of the formula:

$$\mathbf{R}^{1}$$
- \mathbf{N} - \mathbf{C} N- $\mathbf{$

or its salt, wherein, in the above formulas, R^1 are each as defined above, and R^6 is aryl which may be substituted with substituent(s), or pyridyl, or

3) reacting a compound of the formula:

or its salt with a compound of the formula:

or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a

compound of the formula:

$$R^1-N$$
 $N-Y-Q-R^2$ (I)

or its salt, in the above formulas, R¹, R² and Q are each as defined above, or

4) reacting a compound of the formula:

$$R^1-N$$
 $N-Y-Q-OH$ (VIII)

or its reactive derivatives at the carboxy or sulfo group, or a salt thereof with a compound of the formula:

$$H_2N-R^7$$
 (IX)

or its salt to provide a compound of the formula:

or its salt, in the above formulas, R1, A and Qa are each as defined above, and

R⁷ is lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, aryl, or a heterocyclic group, each of which optionally is substituted with a substituents(s).

Claim 17. (New) A pharmaceutical composition, comprising:

a compound of Claim 13, as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 18. (New) A method for the therapeutic treatment of amnesia, dementia or schizophrenia, which comprises:

administering an effective amount of a compound of Claim 13 to mammals.

Claim 19. (New) The compound according to Claim 13, wherein R¹ is lower alkanoyl, benzoyl, benzoyl substituted by halo(lower)alkoxy, phenylsulfonyl, phenylsulfonyl substituted by halogen, lower alkylsulfonyl or cyclo(lower)alkylcarbonyl; R² is lower alkylamino, lower alkenylamino, lower alkynylamino, cyclo(lower)alkylamino, phenylamino or an amino group substituted with pyridyl, each of which is optionally substituted with halogen;

Y is a single bond or lower alkylene; and

Q is -CO- or -SO₂-, and a pharmaceutically acceptable salt thereof.

Claim 20. (New) The compound according to Claim 19, wherein R² is phenylamino which optionally is substituted by halogen, pyridyl, or pyridylamino and Y is a single bond.